Loading...
Loading...
CASI| Name | Value |
|---|---|
| Revenues | 9.8M |
| Cost of Revenue | 4.0M |
| Gross Profit | 5.8M |
| Operating Expense | 15.1M |
| Operating I/L | -9.3M |
| Other Income/Expense | -0.9M |
| Interest Income | 0.1M |
| Pretax | -10.1M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -10.2M |
CASI Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes therapeutics and pharmaceutical products globally. Its key products include EVOMELA, an intravenous formulation of melphalan for multiple myeloma treatment, and a pipeline of investigational products such as CNCT19 for B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma, BI-1206 for solid tumors, and CB-5339 for acute myeloid leukemia. Additionally, the company offers Thiotepa for various stem cell transplants and Octreotide long-acting injectable formulations for neuroendocrine tumors. CASI Pharmaceuticals has licensing and distribution agreements with several partners to support its product commercialization and revenue generation.
